Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

References

• Egger M, Hoenigl M, Thompson GR 3rd, et al. 2022. Let’s talk about sex characteristics - as a risk factor for invasive fungal diseases. Mycoses (In eng), . https://doi.org/10.1111/myc.13449
   Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4(1):18026. DOI:https://doi.org/10.1038/nrdp.2018.26.
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Lass-Flörl C, Garcia-Rubio R, et al. The quiet and underappreciated rise of drug-resistant invasive fungal pathogens. J Fungi. Basel, Switzerland) 2020;6 (In eng. https://doi.org/10.3390/jof6030138.
   Google Scholar
• Flowers SA, Colón B, Whaley SG, et al. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother. 2015;59(1):450–460. In eng. DOI:https://doi.org/10.1128/aac.03470-14
   PubMed Web of Science ®Google Scholar
• Fan X, Xiao M, Zhang D, et al. Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China. Clin Microbiol Infect. 2019;25(7):885–891. In eng. DOI:https://doi.org/10.1016/j.cmi.2018.11.007
   PubMed Web of Science ®Google Scholar
• Muñoz JF, Gade L, Chow NA, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346. In eng. DOI:https://doi.org/10.1038/s41467-018-07779-6
   PubMed Web of Science ®Google Scholar
• Nishimoto AT, Sharma C, Rogers PD. Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans. J Antimicrob Chemother. 2020;75(2):257–270. In eng. DOI:https://doi.org/10.1093/jac/dkz400
   PubMed Web of Science ®Google Scholar
• Iyer KR, Camara K, Daniel-Ivad M, et al. An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris. Nat Commun. 2020;11(1):6429. In eng. DOI:https://doi.org/10.1038/s41467-020-20183-3
   PubMed Web of Science ®Google Scholar
• Ferrari S, Sanguinetti M, De Bernardis F, et al. Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemother. 2011;55(5):1852–1860. In eng. DOI:https://doi.org/10.1128/aac.01271-10
   PubMed Web of Science ®Google Scholar
• Siscar-Lewin S, Gabaldón T, Aldejohann AM, et al. Transient mitochondria dysfunction confers fungal cross-resistance against phagocytic killing and fluconazole. mBio. 2021;12(3):e0112821. In eng. DOI:https://doi.org/10.1128/mBio.01128-21
   PubMedGoogle Scholar
• Hou X, Healey KR, Shor E, et al. Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata. Emerg Microbes Infect. 2019;8(1):1619–1625. In eng. DOI:https://doi.org/10.1080/22221751.2019.1684209
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Daneshnia F, Salehi M, et al. Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure. Mycoses. 2020;63(9):911–920. In eng. DOI:https://doi.org/10.1111/myc.13104
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52(7):2305–2312. In eng. DOI:https://doi.org/10.1128/aac.00262-08
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Daneshnia F, Hilmioglu-Polat S, et al. Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge? J Antimicrob Chemother. 2021;76(2):418–422. In eng. DOI:https://doi.org/10.1093/jac/dkaa419
   PubMed Web of Science ®Google Scholar
• Liu TT, Lee RE, Barker KS, et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother. 2005;49(6):2226–2236. In eng. DOI:https://doi.org/10.1128/aac.49.6.2226-2236.2005
   PubMed Web of Science ®Google Scholar
• Silva LN, Oliveira SSC, Magalhães LB, et al. Unmasking the amphotericin B resistance mechanisms in Candida haemulonii species complex. ACS Infect Dis. 2020;6(5):1273–1282. In eng. DOI:https://doi.org/10.1021/acsinfecdis.0c00117
   PubMedGoogle Scholar
• Kannan A, Asner SA, Trachsel E, et al. Comparative genomics for the elucidation of multidrug resistance in Candida lusitaniae. mBio. 2019;10(6):In eng. DOI:https://doi.org/10.1128/mBio.02512-19.
   Web of Science ®Google Scholar
• Gao J, Chow EWL, Wang H, et al. LncRNA DINOR is a virulence factor and global regulator of stress responses in Candida auris. Nat Microbiol. 2021;6(7):842–851. In eng. DOI:https://doi.org/10.1038/s41564-021-00915-x
   PubMed Web of Science ®Google Scholar
• Hovhannisyan H, Gabaldón T. The long non-coding RNA landscape of Candida yeast pathogens. Nat Commun. 2021;12(1):7317. In eng. DOI:https://doi.org/10.1038/s41467-021-27635-4
   PubMed Web of Science ®Google Scholar
• Todd RT, Selmecki A. Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs. eLife. 2020;9. DOI:https://doi.org/10.7554/eLife.58349. In eng.
   Google Scholar
• Berman J, Krysan DJ. Drug resistance and tolerance in fungi. Nat Rev Microbiol. 2020;18(6):319–331. In eng. DOI:https://doi.org/10.1038/s41579-019-0322-2
   PubMed Web of Science ®Google Scholar
• Healey KR, Perlin DS. Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata. J Fungi. 2018;4. Basel, Switzerland) ; (In eng. doi:https://doi.org/10.3390/jof4030105
   Google Scholar
• Healey KR, Zhao Y, Perez WB, et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun. 2016;7(1):11128. In eng. DOI:https://doi.org/10.1038/ncomms11128
   PubMedGoogle Scholar
• Yadav A, Singh A, Wang Y, et al. Colonisation and transmission dynamics of candida auris among chronic respiratory diseases patients hospitalised in a chest hospital, Delhi, India: a comparative analysis of whole genome sequencing and microsatellite typing. J Fungi (Basel). 2021;7(2). In eng. DOI:https://doi.org/10.3390/jof7020081.
   Google Scholar
• Bordallo-Cardona M, Agnelli C, Gómez-Nuñez A, et al. MSH2 gene point mutations are not antifungal resistance markers in Candida glabrata. Antimicrob Agents Chemother. 2019;63(1). In eng. DOI:https://doi.org/10.1128/aac.01876-18.
   Google Scholar
• Dellière S, Healey K, Gits-Muselli M, et al. Fluconazole and echinocandin resistance of candida glabrata correlates better with antifungal drug exposure rather than with MSH2 mutator genotype in a French cohort of patients harboring low rates of resistance. Front Microbiol. 2016;7:2038. In eng. DOI:https://doi.org/10.3389/fmicb.2016.02038
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel). 2020;6(4). DOI:https://doi.org/10.3390/jof6040239
   Google Scholar
• Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703–1729. DOI:https://doi.org/10.1007/s40265-021-01611-0.
   PubMed Web of Science ®Google Scholar
• Hata K, Horii T, Miyazaki M, et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother. 2011;55(10):4543–4551. In eng. DOI:https://doi.org/10.1128/aac.00366-11
   PubMed Web of Science ®Google Scholar
• Watanabe NA, Miyazaki M, Horii T, et al. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2012;56(2):960–971.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Chowdhary A, Jorgensen KM, et al. (APX001A) in vitro activity against candida auris: head-to-head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother. 2020;64(10). DOI:https://doi.org/10.1128/AAC.00656-20. .
   Google Scholar
• Arendrup MC, Jorgensen KMM. (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs. Antimicrob Agents Chemother. 2020;64(7). DOI:https://doi.org/10.1128/AAC.00429-20
   Google Scholar
• Pfaller MA, Hata K, Jones RN, et al. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Diagn Microbiol Infect Dis. 2011;71(2):167–170.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Flamm RK, et al. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019). J Glob Antimicrob Resist. 2021;26:117–127.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Shaw KJ, et al. Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a murine model of Candida auris invasive Candidiasis. Antimicrob Agents Chemother. 2019;63(11). DOI:https://doi.org/10.1128/AAC.01120-19
   Web of Science ®Google Scholar
• Zhu Y, Kilburn S, Kapoor M, et al. In vitro activity of manogepix against multidrug-resistant and pan resistant Candida auris from the New York outbreak. Antimicrob Agents Chemother. 2020;64(11). DOI:https://doi.org/10.1128/AAC.01124-20
   Google Scholar
• Kapoor M, Moloney M, Soltow QA, et al. Evaluation of resistance development to the Gwt1 inhibitor manogepix (APX001A) in Candida species. Antimicrob Agents Chemother. 2019;64(1). DOI:https://doi.org/10.1128/AAC.01387-19
   Google Scholar
• Liston SD, Whitesell L, Kapoor M, et al. Enhanced efflux pump expression in Candida mutants results in decreased manogepix susceptibility. Antimicrob Agents Chemother. 2020;64(5). DOI:https://doi.org/10.1128/AAC.00261-20
   Web of Science ®Google Scholar
• Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61(5). In eng. DOI:https://doi.org/10.1128/aac.02396-16.
   Google Scholar
• Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62(3). DOI:https://doi.org/10.1128/AAC.02319-17
   Google Scholar
• Zhao M, Lepak AJ, VanScoy B, et al. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother. 2018;62(4). DOI:https://doi.org/10.1128/AAC.02542-17
   Google Scholar
• Lee A, Wang N, Carter CL, et al. Therapeutic potential of fosmanogepix (APX001) for intra-abdominal Candidiasis: from lesion penetration to efficacy in a mouse model. Antimicrob Agents Chemother. 2021;65(4). DOI:https://doi.org/10.1128/AAC.02476-20
   Google Scholar
• Hodges MR, Ople E, Shaw KJ, et al. Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability. Open Forum Infect Dis. Issue suppl_1, Fall 2017, S534, https://doi.org/10.1093/ofid/ofx163.1390 Published 04 October 2017;4suppl_1
   Google Scholar
• Pappas PG, Kullberg BJ, Vazquez JA, et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, in the treatment of Candidemia: results from a phase 2 proof of concept trial. In: IDWeek 2020. Programs and Abstracts of the 55th Annual Infectious Diseases Society of America (IDSA) Meeting. Philadelphia PA: October 2020. Selected for Oral Presentation
   Google Scholar
• Bulpa P, Rahav G, Oren I, et al. Clinical safety and efficacy of fosmanogepix, a novel first-in-class antifungal, in patients with renal insufficiency: subset analysis from a phase 2 Candidemia trial. In: IDWeek 2020. Programs and Abstracts of the 55th Annual Infectious Diseases Society of America (IDSA) Meeting. Philadelphia PA: October 2020. Poster #1157.
   Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002;46(9):3001–3012. In eng. DOI:https://doi.org/10.1128/aac.46.9.3001-3012.2002
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Long L, Larkin EL, et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. Antimicrob Agents Chemother. 2018;62(6). In eng. DOI:https://doi.org/10.1128/aac.00244-18.
   Google Scholar
• Schell WA, Jones AM, Borroto-Esoda K, et al. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):In eng. DOI:https://doi.org/10.1128/aac.01102-17.
   Google Scholar
• Jiménez-Ortigosa C, Perez WB, Angulo D, et al. De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance. Antimicrob Agents Chemother. 2017;61(9):In eng. DOI:https://doi.org/10.1128/aac.00833-17.
   Google Scholar
• Nunnally NS, Etienne KA, Angulo D, et al. In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations. Antimicrob Agents Chemother. 2019;63(11). DOI:https://doi.org/10.1128/AAC.01692-19
   Google Scholar
• Ghannoum M, Long L, Isham N, et al. Activity of a novel 1,3-beta-D-glucan synthase inhibitor, ibrexafungerp (formerly SCY-078), against Candida glabrata. Antimicrob Agents Chemother. 2019;63(12). In eng. DOI:https://doi.org/10.1128/aac.01510-19.
   Google Scholar
• Jiménez-Ortigosa C, Paderu P, Motyl MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob Agents Chemother. 2014;58(2):1248–1251. In eng. DOI:https://doi.org/10.1128/aac.02145-13
   PubMed Web of Science ®Google Scholar
• Marcos-Zambrano LJ, Gomez-Perosanz M, Escribano P, et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017;72(7):1969–1976.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother. 2017;61(8):In eng. DOI:https://doi.org/10.1128/aac.00161-17.
   Google Scholar
• Jallow S, Govender NP. Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor. J Fungi (Basel). 2021;7(3). DOI:https://doi.org/10.3390/jof7030163
   Google Scholar
• Zhu YC, Barat SA, Borroto-Esoda K, et al. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922. In eng. DOI:https://doi.org/10.1016/j.ijantimicag.2020.105922
   PubMed Web of Science ®Google Scholar
• Wring SA, Randolph R, Park S, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated Candidiasis. Antimicrob Agents Chemother. 2017;61(4). In eng. DOI:https://doi.org/10.1128/aac.02068-16.
   Google Scholar
• Gamal A, Chu S, McCormick TS, et al. Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata. Front Cell Infect Microbiol. 2021;11:642358. DOI:https://doi.org/10.3389/fcimb.2021.642358. In eng.
   PubMed Web of Science ®Google Scholar
• Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: a novel oral glucan synthase inhibitor. Med Mycol. 2020;58(5):579–592. In eng. DOI:https://doi.org/10.1093/mmy/myz083
   PubMed Web of Science ®Google Scholar
• Wring S, Borroto-Esoda K, Solon E, et al. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [(14)C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother. 2019;63(2):In eng. DOI:https://doi.org/10.1128/aac.02119-18.
   Google Scholar
• FDA. BREXAFEMME® (ibrexafungerp tablets), for oral use. Initial US Approval: 2021.
   Google Scholar
• Schwebke JR, Sorkin-Wells V, Azie N, et al. Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: a phase 3, randomized, blinded, study vs. placebo (VANISH-303). Am J Obstet Gynecol. 2020;223(6):964–965.
   Google Scholar
• U.S. Food and Drug Administration CfDEaR. NDA Multi-disciplinary Review and Evaluation - NDA 214900; BREXAFEMME (ibrexafungerp). [cited 2022 Feb 12]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf.
   Google Scholar
• Spec A, Pullman J, Thompson GR, et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019;74(10):3056–3062. DOI:https://doi.org/10.1093/jac/dkz277.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Koehler P, Pappas P, et al. Outcomes of oral ibrexafungerp in 33 patients with refractory fungal diseases, interim analysis of a phase III open-label study (FURI) 31st ECCMID 2021. Online: ESCMID eLearning; 2021.
   Google Scholar
• Juneja D, Ross C, Breedt J, et al. Outcomes of oral ibrexafungerp in the treatment of ten patients with Candida auris infections, from the CARES Study. 31st ECCMID 20212021.
   Google Scholar
• James KD, Laudeman CP, Malkar NB, et al. Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties. Antimicrob Agents Chemother. 2017;61(2):In eng. DOI:https://doi.org/10.1128/aac.01541-16.
   Google Scholar
• Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother. 2016;60(11):6872–6879. In eng. DOI:https://doi.org/10.1128/aac.00701-16
   PubMed Web of Science ®Google Scholar
• Sandison T, Ong V, Lee J, et al. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61(2):In eng. DOI:https://doi.org/10.1128/aac.01627-16.
   Google Scholar
• Zhao Y, Prideaux B, Nagasaki Y, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother. 2017;61(10). In eng. DOI:https://doi.org/10.1128/aac.01009-17.
   Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 antifungal surveillance program. Int J Antimicrob Agents. 2017;50(3):352–358. In eng. DOI:https://doi.org/10.1016/j.ijantimicag.2017.03.028
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Meletiadis J, Zaragoza O, et al. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method. Clin Microbiol Infect. 2018;24(11):1200–1204. In eng. DOI:https://doi.org/10.1016/j.cmi.2018.02.021
   PubMed Web of Science ®Google Scholar
• Helleberg M, Jørgensen KM, Hare RK, et al. Rezafungin in vitro activity against contemporary nordic clinical candida isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2020;64(4):In eng. DOI:https://doi.org/10.1128/aac.02438-19.
   Google Scholar
• Tóth Z, Forgács L, Locke JB, et al. In vitro activity of rezafungin against common and rare Candida species and saccharomyces cerevisiae. J Antimicrob Chemother. 2019;74(12):3505–3510. In eng. DOI:https://doi.org/10.1093/jac/dkz390
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother. 2016;71(10):2868–2873. In eng. DOI:https://doi.org/10.1093/jac/dkw214
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, VanScoy B, et al. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. Antimicrob Agents Chemother. 2018;62(2):In eng. DOI:https://doi.org/10.1128/aac.02154-17.
   Google Scholar
• Hager CL, Larkin EL, Long LA, et al. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018;73(8):2085–2088. In eng. DOI:https://doi.org/10.1093/jac/dky153
   PubMed Web of Science ®Google Scholar
• Flanagan S, Goodman DB, Jandourek A, et al. Lack of effect of rezafungin on QT/QTc interval in healthy subjects. Clin Pharmacol Drug Dev. 2020;9(4):456–465. In eng. DOI:https://doi.org/10.1002/cpdd.757
   PubMed Web of Science ®Google Scholar
• Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of Candidemia and invasive candidiasis- the STRIVE trial. Clin Infect Dis. 2020;In eng. DOI:https://doi.org/10.1093/cid/ciaa1380.
   Google Scholar
• Positive phase 3 results of rezafungin for treating candidemia and invasive Candidiasis. (https://www.contagionlive.com/view/positive-phase-3-results-of-rezafungin-for-treating-candidemia-and-invasive-candidiasis) Accessed 06.January.2022.
   Google Scholar
• Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC. (http://ir.cidara.com/node/6481/pdf) 12.January.2022.
   Google Scholar
• Aigner M, Lass-Florl C. Encochleated amphotericin b: is the oral availability of amphotericin B finally reached? J Fungi (Basel). 2020;6(2). DOI:https://doi.org/10.3390/jof6020066
   Google Scholar
• Santangelo R, Paderu P, Delmas G, et al. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother. 2000;44(9):2356–2360.
   PubMed Web of Science ®Google Scholar
• Kipathi L, Kumar P, et al. A phase lla efficacy safety, tolerability and pharmacokinetic study of encochleated amphotericin B in patients with mucocutaneous (esophageal, oropharyngeal, vulvovaginal) Candidiasis who are refractory or intolerant to standard non-intravenous therapies. Open Forum Infect Dis. 2018;5:5435–5436.
   Google Scholar
• Gov. USNLoMCT. Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the treatment of Vulvo vaginal Candidiasis (VVC). NCT02971007 (https://clinicaltrials.gov/ctz/show/nct02971007 ( accessed February/2022)).
   Google Scholar
• McCarty TP, Pappas PG. 2021. Antifungal pipeline. Front Cell Infect Microbiol ;11 (Review) (In English). doi:https://doi.org/10.3389/fcimb.2021.732223.
   Google Scholar
• Hoekstra WJ, Garvey EP, Moore WR, et al. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett. 2014;24(15):3455–3458.
   PubMed Web of Science ®Google Scholar
• Warrilow AG, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121–7127.
   PubMed Web of Science ®Google Scholar
• Nishimoto AT, Whaley SG, Wiederhold NP, et al. Impact of the major candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob Agents Chemother. 2019;63(10). DOI:https://doi.org/10.1128/AAC.01304-19
   Web of Science ®Google Scholar
• Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63(6). DOI:https://doi.org/10.1128/AAC.00341-19
   Web of Science ®Google Scholar
• Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624 e1–624 e9.
   PubMed Web of Science ®Google Scholar
• Brand SR, Sobel JD, Nyirjesy P, et al. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2021;73(7):e1518–e1524. DOI:https://doi.org/10.1093/cid/ciaa1204.
   PubMed Web of Science ®Google Scholar
• Elewski B, Brand S, Degenhardt T, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2021;184(2):270–280.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Nyirjesy P. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol. 2021;16(18):1453–1461.
   PubMedGoogle Scholar
• Lanteri CA, Trumpower BL, Tidwell RR, et al. DB75, a novel trypanocidal agent, disrupts mitochondrial function in saccharomyces cerevisiae. Antimicrob Agents Chemother. 2004;48(10):3968–3974.
   PubMed Web of Science ®Google Scholar
• Yamada E, Nishikawa H, Nomura N, et al. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother. 2010;54(9):3630–3634.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Miyazaki T, Fukuda Y, et al. The novel arylamidine t-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. Antimicrob Agents Chemother. 2019;63(8). In eng. DOI:https://doi.org/10.1128/aac.00374-19.
   Google Scholar
• Shibata T, Takahashi T, Yamada E, et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother. 2012;56(11):5892–5897. In eng. DOI:https://doi.org/10.1128/aac.05954-11
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Yamada E, Shibata T, et al. Uptake of T-2307, a novel arylamidine, in Candida albicans. J Antimicrob Chemother. 2010;65(8):1681–1687. In eng. DOI:https://doi.org/10.1093/jac/dkq177
   PubMedGoogle Scholar
• Nishikawa H, Sakagami T, Yamada E, et al. T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2. J Antimicrob Chemother. 2016;71(7):1845–1855. In eng. DOI:https://doi.org/10.1093/jac/dkw095
   PubMed Web of Science ®Google Scholar
• Mitsuyama J, Nomura N, Hashimoto K, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52(4):1318–1324. In eng. DOI:https://doi.org/10.1128/aac.01159-07
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Jaramillo R, et al. The novel arylamidine t-2307 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2020;64(3). DOI:https://doi.org/10.1128/AAC.02198-19.
   Google Scholar
• Nishikawa H, Fukuda Y, Mitsuyama J, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemother. 2017;72(6):1709–1713.
   PubMed Web of Science ®Google Scholar
• Therapeutics A. [cited 2020 Feb 25]. https://www.appilitherapeutics.com/pipeline-overview.
   Google Scholar
• Cilla DPD. email correspondence relating to data on file at appili therapeutics, inc. 2022 March.
   Google Scholar
• Nakamura I, Yoshimura S, Masaki T, et al. ASP2397: a novel antifungal agent produced by acremonium persicinum MF-347833. J Antibiot (Tokyo). 2017;70(1):45–51.
   PubMed Web of Science ®Google Scholar
• Dietl AM, Misslinger M, Aguiar MM, et al. The siderophore transporter sit1 determines susceptibility to the antifungal VL-2397. Antimicrob Agents Chemother. 2019;63(10). DOI:https://doi.org/10.1128/AAC.00807-19
   Google Scholar
• Rauseo AM, Coler-Reilly A, Larson L, et al. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7(2):ofaa016. In eng. DOI:https://doi.org/10.1093/ofid/ofaa016
   PubMed Web of Science ®Google Scholar
• Nakamura I, Ohsumi K, Takeda S, et al. ASP2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against aspergillus species through a specific transporter. Antimicrob Agents Chemother. 2019;63(10). DOI:https://doi.org/10.1128/AAC.02689-18
   Google Scholar
• Wiederhold NP. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 2018;51(3):333–339.
   PubMed Web of Science ®Google Scholar
• Rubino LRS CM, Mammen MP, Hopkins AM, et al. Pharmacokinetic-pharmacodynamic target attainment analysis to support VL-2397 dose selection for a phase 2 trial in patients with invasive aspergillosis. Open Forum Infect Dis. 2017;4(1):S473.
   Google Scholar
• Mammen MP, Armas D, Hughes FH, et al. First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults. Antimicrob Agents Chemother. 2019;63(11). DOI:https://doi.org/10.1128/AAC.00969-19
   Google Scholar
• Kovanda LL, Sullivan SM, Smith LR, et al. Population pharmacokinetic modeling of VL-2397, a novel systemic antifungal agent: analysis of a single- and multiple-ascending-dose study in healthy subjects. Antimicrob Agents Chemother. 2019;63(6). DOI:https://doi.org/10.1128/AAC.00163-19
   Google Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for candida species from 1997-2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–S94.
   PubMedGoogle Scholar
• Risum M, Astvad K, Johansen HK, et al. Update 2016-2018 of the nationwide Danish fungaemia surveillance study: epidemiologic changes in a 15-year perspective. J Fungi (Basel). 2021;7(6). DOI:https://doi.org/10.3390/jof7060491
   Google Scholar
• Fekkar A, Meyer I, Brossas JY, et al. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother. 2013;57(5):2380–2382.
   PubMedGoogle Scholar
• Duncan V, Smith D, Simpson L, et al. Preliminary characterization of NP339, a novel polyarginine peptide with broad antifungal activity. Antimicrob Agents Chemother. 2021;65(8):e0234520.
   PubMedGoogle Scholar
• Kauffman WB, Fuselier T, He J, et al. Mechanism matters: a taxonomy of cell penetrating peptides. Trends Biochem Sci. 2015;40(12):749–764.
   PubMed Web of Science ®Google Scholar
• Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001;276(8):5836–5840.
   PubMed Web of Science ®Google Scholar
• Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17(1):134–143.
   PubMed Web of Science ®Google Scholar
• Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: application informed by evolution. Science. 2020;368(6490). DOI:https://doi.org/10.1126/science.aau5480
   Google Scholar
• Palic S, Beijnen JH, Dorlo TPC. An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. Int J Antimicrob Agents. 2022;59(1):106459.
   PubMedGoogle Scholar
• Widmer F, Wright LC, Obando D, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother. 2006;50(2):414–421.
   PubMed Web of Science ®Google Scholar
• Vila T, Ishida K, Seabra SH, et al. Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells. Int J Antimicrob Agents. 2016;48(5):512–520.
   PubMed Web of Science ®Google Scholar
• Barreto TL, Rossato L, de Freitas ALD, et al. Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. Int J Antimicrob Agents. 2020;56(2):106049.
   PubMed Web of Science ®Google Scholar
• Wu Y, Totten M, Memon W, et al. In vitro antifungal susceptibility of the emerging multidrug-resistant pathogen candida auris to miltefosine alone and in combination with amphotericin B. Antimicrob Agents Chemother. 2020;64(2). DOI:https://doi.org/10.1128/AAC.02063-19
   Google Scholar
• Wu Y, Wu M, Gao J, et al. Antifungal activity and mode of action of miltefosine against clinical isolates of Candida krusei. Front Microbiol. 2020;11:854.
   PubMedGoogle Scholar
• Sean A. Bergin FZ, Adam PR, Müller CA, et al. Resistance to miltefosine results from amplification of the RTA3 floppase or inactivation of flippases in Candida parapsilosis. 2021.
   Google Scholar
• Spadari CC, de Bastiani F, Lopes LB, et al. Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis. Int J Nanomedicine. 2019;14:5187–5199.
   PubMed Web of Science ®Google Scholar
• de Bastiani F, Spadari CC, de Matos Jkr, et al. Nanocarriers provide sustained antifungal activity for amphotericin b and miltefosine in the topical treatment of murine vaginal candidiasis. Front Microbiol. 2019;10:2976.
   PubMedGoogle Scholar
• (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=843921 ( Accessed February/2022)).
   Google Scholar
• Cornely OA, Hoenigl M, Lass-Florl C, et al. Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European confederation of medical mycology. Mycoses. 2019;62(9):716–729. In eng. DOI:https://doi.org/10.1111/myc.12960
   PubMed Web of Science ®Google Scholar